Trade Lyra Therapeutics, Inc. - LYRA CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.05 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.02629% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.004068% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | N/A |
| Open | N/A |
| 1-Year Change | N/A |
| Day's Range | N/A |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| May 17, 2024 | 0.38 | -0.01 | -2.56% | 0.39 | 0.39 | 0.38 |
| May 7, 2024 | 0.41 | 0.00 | 0.00% | 0.41 | 0.46 | 0.40 |
| May 6, 2024 | 0.50 | 0.12 | 31.58% | 0.38 | 0.61 | 0.37 |
| May 3, 2024 | 3.99 | -0.65 | -14.01% | 4.64 | 4.69 | 3.91 |
| May 2, 2024 | 4.59 | -0.54 | -10.53% | 5.13 | 5.19 | 4.57 |
| May 1, 2024 | 5.23 | 0.26 | 5.23% | 4.97 | 5.57 | 4.97 |
| Apr 30, 2024 | 5.13 | 0.40 | 8.46% | 4.73 | 5.15 | 4.65 |
| Apr 29, 2024 | 4.68 | 0.05 | 1.08% | 4.63 | 4.98 | 4.63 |
| Apr 26, 2024 | 4.70 | -0.38 | -7.48% | 5.08 | 5.11 | 4.68 |
| Apr 25, 2024 | 5.15 | -0.01 | -0.19% | 5.16 | 5.24 | 5.10 |
| Apr 24, 2024 | 5.20 | 0.01 | 0.19% | 5.19 | 5.30 | 5.10 |
| Apr 23, 2024 | 5.18 | 0.00 | 0.00% | 5.18 | 5.35 | 5.13 |
| Apr 22, 2024 | 5.17 | 0.06 | 1.17% | 5.11 | 5.24 | 5.05 |
| Apr 19, 2024 | 5.13 | -0.02 | -0.39% | 5.15 | 5.44 | 5.08 |
| Apr 18, 2024 | 5.34 | -0.04 | -0.74% | 5.38 | 5.47 | 5.18 |
| Apr 17, 2024 | 5.37 | 0.09 | 1.70% | 5.28 | 5.72 | 5.22 |
| Apr 16, 2024 | 5.37 | 0.23 | 4.47% | 5.14 | 5.44 | 5.13 |
| Apr 15, 2024 | 5.23 | -0.03 | -0.57% | 5.26 | 5.35 | 5.16 |
| Apr 12, 2024 | 5.26 | 0.03 | 0.57% | 5.23 | 5.51 | 5.12 |
| Apr 11, 2024 | 5.42 | 0.17 | 3.24% | 5.25 | 5.45 | 5.23 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Lyra Therapeutics, Inc. Company profile
About Lyra Therapeutics Inc
Lyra Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on development and commercialization of novel drug and delivery solutions for the treatment of patients with ear, nose, and throat (ENT) diseases. Its technology platform, XTreo, is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. Its product candidates include LYR-210 and LYR-220, are bioresorbable polymeric matrices administered in a non-invasive, in-office procedure to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis (CRS). LYR-210 is an anti-inflammatory implantable drug matrix based on its XTreo platform that is designed to elute mometasone furoate (MF) to the inflamed mucosal tissue for up to six months in surgically naive CRS patients. LYR-220 is an investigative therapy for CRS patients with and without nasal polyps.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Lyra Therapeutics Inc revenues increased from $0K to $285K. Net loss applicable to common stockholders increased 96% to $43.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balancing val increase from $12.3M to $29.2M (expense).
| Industry: | Biotechnology & Medical Research (NEC) |
480 Arsenal Way
WATERTOWN
MASSACHUSETTS 02472
US
News
How to manage risk when trading
Learn what risk management is and find out how understanding about it could help you identify potential risks in your investment portfolio. Find out more.
06:57, 22 July 2024
ECB preview: lack of new data sees markets expecting a hold
Markets expect the ECB to keep rates unchanged in July but expectations for a September cut rise
13:13, 18 July 2024
What is an IPO and how does it work?
Learn about what an IPO is, why they are important, and how they work.
07:19, 10 July 2024
What are the biggest stock exchanges worldwide?
Discover the largest stock exchanges in the world by market capitalisation, including the Nasdaq Stock Market, the New York Stock Exchange and the London Stock Exchange.
12:44, 9 July 2024
Top ETFs
ETFs, or exchange-traded funds, offer traders a versatile gateway into the financial markets.
16:23, 8 July 2024
Lloyds forecast: will Lloyds share price return to £1? Third party data forecast
What’s next for Lloyds amid higher inflation and the start of a potential recessionary cycle in the UK?
14:00, 8 July 2024
RBNZ Preview: OCR expected to remain unchanged as central bank focuses on inflation
The Reserve Bank of New Zealand meets on Wednesday, July 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
13:25, 8 July 2024People also watch
Still looking for a broker you can trust?
Join the 630,000+ traders worldwide that chose to trade with Capital.com